| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | Lifetime | 161 | JP 11 | 98.94 |
| Pediatric health and respiratory diseases | Lifetime | 230 | JP 3 | 98.42 |
| COVID-19 Clinical Research Studies | Lifetime | 846 | JP 15 | 97.13 |
| Pneumonia and Respiratory Infections | Lifetime | 649 | JP 6 | 97.88 |
| Inhalation and Respiratory Drug Delivery | Lifetime | 353 | JP 3 | 97.34 |
| Antimicrobial Peptides and Activities | Lifetime | 544 | JP 35 | 96.22 |
| Medical Imaging and Pathology Studies | Lifetime | 892 | JP 106 | 95.99 |
| Pleural and Pulmonary Diseases | Lifetime | 512 | JP 37 | 96.11 |
| Eosinophilic Disorders and Syndromes | Lifetime | 568 | JP 37 | 96.08 |
| Sarcoidosis and Beryllium Toxicity Research | Lifetime | 450 | JP 46 | 94.43 |
| Nosocomial Infections in ICU | Lifetime | 680 | JP 10 | 93.99 |
| Occupational and environmental lung diseases | Lifetime | 904 | JP 40 | 92.68 |
| Inflammatory Myopathies and Dermatomyositis | Lifetime | 720 | JP 83 | 91.57 |
| Otolaryngology and Infectious Diseases | Lifetime | 616 | JP 21 | 82.32 |
| COVID-19 Clinical Research Studies | 2021-2025 | 588 | JP 8 | 97.41 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 816 | JP 22 | 96.89 |
| Pneumonia and Respiratory Infections | 2021-2025 | 236 | JP 1 | 94.92 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | 2021-2025 | 283 | JP 23 | 94.92 |
| Nosocomial Infections in ICU | 2021-2025 | 103 | JP 6 | 92.50 |
| Antifungal resistance and susceptibility | 2021-2025 | 484 | JP 12 | 90.79 |
| SARS-CoV-2 detection and testing | 2021-2025 | 824 | JP 44 | 88.26 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 464 | JP 7 | 85.67 |
| Pediatric health and respiratory diseases | 2021-2025 | 343 | JP 11 | 83.57 |
| Mycobacterium research and diagnosis | 2021-2025 | 709 | JP 30 | 85.49 |
| Fungal Infections and Studies | 2021-2025 | 631 | JP 12 | 85.66 |
| Respiratory and Cough-Related Research | 2021-2025 | 660 | JP 25 | 80.97 |
| Medical Imaging and Pathology Studies | 2021-2025 | 830 | JP 98 | 75.06 |
| Sarcoidosis and Beryllium Toxicity Research | 2021-2025 | 610 | JP 80 | 77.43 |
| Streptococcal Infections and Treatments | 2021-2025 | 923 | JP 44 | 74.38 |
| Occupational and environmental lung diseases | 2021-2025 | 633 | JP 52 | 75.64 |
| Occupational exposure and asthma | 2021-2025 | 368 | JP 24 | 68.97 |
| Infectious Diseases and Mycology | 2021-2025 | 560 | JP 45 | 66.78 |
| Soft tissue tumor case studies | 2021-2025 | 780 | JP 63 | 50.08 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 798 | JP 253 | 43.75 |
| Histiocytic Disorders and Treatments | 2021-2025 | 924 | JP 54 | 25.13 |
| Diphtheria, Corynebacterium, and Tetanus | 2021-2025 | 455 | JP 22 | 18.88 |
